AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Guanosine-rich PO ODN may be alternative approach to development.(phosphodiester oligodeoxynucleotides for vaccine adjuvants)(Brief Article)
2003 APR 16 - (NewsRx.com & NewsRx.net) -- Guanosine-rich phosphodiester oligodeoxynucleotides (PO ODN) may be an alternative approach to the development of effective and safe vaccine adjuvants, say microbiologists at the University of Marburg.
"The immunostimulatory activity of oligonucleotides containing CpG motifs is well established and represents the basis for an effective vaccine adjuvant. For use in vivo, CpG ODN have to be protected from the attack of nucleases to ensure sustained effectiveness. This is usually accomplished by phosphothioate (PTO) modifications of the ODN's backbone. However, PTO modification may induce undesired effects," said S. Zimmermann and associates.
They tried supplementing the ODN's sequence to "enhance the immunostimulatory activity of CpG phosphodiester ODN."
The researchers reported "that addition of poly-guanosine runs to the 3'-end of a CpG-PO ODN conveys immunostimulatory activity to CpG-PO ODN in vivo ...
- Vaccine Adjuvants and Delivery Systems: The Authoritative Reference on Recent...
- Press release article from: M2 Presswire November 4, 2009 700+ words
...Research and Markets: Vaccine Adjuvants and Delivery Systems...com/research/4f5db5/vaccine_adjuvants) has announced the addition...Sons Ltd's new report "Vaccine Adjuvants and Delivery Systems...
- New Book Addresses Issues In Relation To Existing Vaccine Adjuvants, Those In...
- Press release article from: M2 Presswire October 26, 2007 700+ words
...Addresses Issues In Relation To Existing Vaccine Adjuvants, Those In Clinical Trials, And...c72858) has announced the addition of Vaccine Adjuvants and Delivery Systems to their offering...these issues in relation to existing vaccine adjuvants, those in clinical trials, and...
- SRI AND GENESIS TECHNOLOGY FORM JOINT VENTURE TO DEVELOP PEDIATRIC VACCINE...
- Press release article from: PR Newswire November 15, 1993 700+ words
...which is developing pediatric vaccine adjuvants derived from glucans, polymers composed...anticipate that many of the newer vaccine adjuvants will have side effects that may be...proprietary glucans have been studied as vaccine adjuvants in both rabbits and mice, demonstrating...
- 3M Collaborates with Infectious Disease Research Institute on Vaccine Adjuvants.
- Press release article from: Business Wire May 1, 2008 700+ words
...compounds, which may be useful as vaccine adjuvants, will be used by IDRI to research new vaccines. Vaccine adjuvants are known to help boost the effectiveness...potential effectiveness of our vaccine adjuvants. We anticipate this collaboration...
- Cell death induced by vaccine adjuvants containing surfactants.
- Newspaper article from: Immunotherapy Weekly June 23, 2004 700+ words
...Cell death was induced by vaccine adjuvants containing surfactants...study from Taiwan, "Many vaccine adjuvants contain surface-active...Vaccine (Cell death induced by vaccine adjuvants containing surfactants...
- 3M Licenses Vaccine Adjuvants to VaxInnate.
- Press release article from: Business Wire November 9, 2009 700+ words
...patented toll-like receptor (TLR) agonists for use as vaccine adjuvants. Data suggest that 3M's TLR agonists could enhance vaccine...receptor TLR7 and TLR8 agonists that have shown promise as vaccine adjuvants. There are a variety of assets in the portfolio that can...
- 3M Licenses Vaccine Adjuvants to Sanofi Pasteur.
- Press release article from: Business Wire October 7, 2008 700+ words
...undisclosed licensing fee, milestones and royalties for use as vaccine adjuvants. 3M's patented TLR immune response modifier compounds...receptor TLR7 and TLR8 agonists that have shown promise as vaccine adjuvants. There are a variety of assets in the portfolio that can...
- Stakeholder Opinions - Vaccine adjuvants - uncertainties rule.
- Press release article from: M2 Presswire November 6, 2008 700+ words
...www.companiesandmarkets.com: Stakeholder Opinions - Vaccine adjuvants - uncertainties rule(C)1994-2008 M2 COMMUNICATIONS...companiesandmarkets.com adds new report: Stakeholder Opinions - Vaccine adjuvants - uncertainties rule Introduction Adjuvants are coming...
Source: HighBeam Research, Guanosine-rich PO ODN may be alternative approach to...